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Zinc for the common cold:
The zinc for the common cold review by Singh and Das has a number of problems 
which should be considered when the review is next time updated
Harri Hemilä
Department of Public Health
University of Helsinki
Finland
1) Search of the studies
Eby and Halcomb (2006) reported a randomized double-blind placebo-controlled trial on zinc for 
the common cold [1], which is missing from the review. The trial is included in MEDLINE (PMID: 
16454145) and Singh and Das should have found it and listed among the trials requiring an 
assessment.
2) Extraction of data
Singh and Das describe that “The lead review author (MS) entered data directly into Review 
Manager. An independent coder verified accuracy of data entry”. However, looking at their 
Analysis 1.1 led me to wonder how can they claim that the findings of the Petrus (1998) trial were 
non-significant (the 95%CI covering the “no effect”), given that Petrus (1998 p. 600) wrote that 
“t-test showed that the mean duration of all symptoms was significantly lower in the zinc group 
(3.8±0.2 days) than in the placebo group (5.1±0.4 days)(P=0.008)”. In their Analysis 1.1, Singh 
and Das give the mean duration of colds in the zinc group as 4.4 days, and not as the 3.8 days 
reported by Petrus (above). The value of 4.4 days is given in the Petrus (1998) Table II as the 
overall mean duration of colds, i.e. the mean for all zinc and placebo participants combined, 
but Table II also gives the 3.8 days for the duration of colds in the zinc group. 
In their paper, Petrus (1998) gives the accuracy of the mean as the SE (standard error), 
whereas the Review Manager needs the SD (standard deviation). The SE values reported by Petrus 
(1998) are highly inaccurate (above), yet Singh and Das calculated the corresponding SD estimates 
from them. To get the accurate Petrus (1998) trial results, I contacted the statistician of the group 
and got their results: 3.797 (SD 1.630) days in the zinc group and 5.106 (SD 2.955) in the placebo 
group (Ken Lawson, email 4 Mar 2009). The Petrus (1998) values in Analysis 1.1 should be 
replaced with these correct and accurate values.
3) The characteristics of included studies table
In the Characteristics of included studies table, Singh and Das write about the Al-Nakib (1987) trial 
that there was “unclear risk” for the item “incomplete outcome data addressed?”. However, Singh 
and Das write that “there were no drop-outs or withdrawals”. Lack of drop-outs does not justify 
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their judgment (“unclear risk”). Furthermore, Singh and Das state that in the Al-Nakib trial there is 
“high risk” for the item “free of selective reporting?”. The statement that there is “high risk” calls 
for justification, whereas none is given. Furthermore, Singh and Das list six outcomes for the 
Al-Nakib (1987) trial, yet only one of them is relevant to the review: “the severity of symptoms”. 
However, I cannot see this outcome in any of their Analysis tables. The outcome section of the 
included studies table should list only those outcomes that are used in the review. Furthermore, it 
would help the reader if the included studies table describes in which Analysis the values of the 
outcomes are presented. 
Singh and Das state that in the Smith (1987) trial there is “low risk” for the item “incomplete  
outcome data addressed?”. Smith started with 176 participants and reported the results for only 
110 participants, which means that they reported data for only 62% of the initial participants. In 
their Methods section, Singh and Das write that “we considered that incomplete outcome data had 
been adequately addressed if 85% or more of the participants were included in the analysis, or if 
less than 85% were included but adequate steps were taken to ensure or demonstrate that this did 
not bias the results.” In their included studies table, Singh and Das do not describe why the analysis 
of 62% of initial participants is acceptable for the Smith (1987) trial although they give the limit of 
85% in their Methods. Stating that the Smith (1987) trial has “low risk” with the 38% drop-out rate, 
and the Al-Nakib (1987) trial has “unclear risk” with no drop-outs (above) is puzzling. 
Singh and Das use an inclusion criterion “randomized controlled trials”. Weismann (1990) 
did not report the method of allocation in their trial report. Nevertheless, Singh and Das describe in 
their included studies table the Weismann (1990) trial: “Methods: randomized trial”. Since their 
report did not describe the method of allocation, I contacted Kaare Weismann, who wrote to me 
“It was a consequetive allocated study with the same number of patient in the two groups” (email 
2 Jul 2010). Thus, the Weismann (1990) trial was not randomized. Given their inclusion criteria, 
Singh and Das should exclude the Weismann trial or they should rewrite the inclusion criteria so 
that they also include pseudo-randomized trials which have used, for example, alternative 
allocation.
Furthermore, Singh and Das state that there is “unclear risk” for the item “allocation 
concealment?” in the Weismann (1990) trial, even though the trial was double blind. The term 
double-blind means that both the patients and researchers are unaware of the type of treatment until 
the trial is concluded. Consequently, neither of them can know to which group a patient had been 
allocated. Thus, double-blind means that there must have been allocation concealment. Otherwise 
the patients and researchers could not remain blind after randomization. This same error is seen in 
the description of the Al-Nakib (1987) and Petrus (1998) trials, which also were double-blind trials. 
As a consequence of this error, Figure 1 gives an impression that several studies were 
methodologically less satisfactory than they actually were.
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More details of the trials should be given in the included studies table. For example, in their 
“implications for practice”, Singh and Das state that “We could not find any trials conducted in 
low-income countries, so our results cannot be applied to people living in low-income countries.” 
However, three trials by Kurugol (2006a, 2006b, 2007) were carried out in Turkey, and one trial 
by Vakili (2009) was carried out in Iran. These are low-income countries. According to World Bank 
statistics, the GDP per capita in Turkey and Iran is 80% and 90% lower than in Germany, as an 
example. Thus, the above statement is false although there are countries which are much poorer 
than Turkey and Iran. To help the reader to understand the contexts of the trials, it would be useful 
to describe the country and the settings of the trials. Such information affects the generalization 
of the findings. Studies in Turkey and Iran cannot be directly extrapolated, for example, to the 
western countries.
4) The characteristics of excluded studies table
In the Characteristics of excluded studies table, Singh and Das comment on the Eby (1984) trial: 
“Intention-to-treat analyses were not conducted; analyses were only conducted on a subset of those 
originally enrolled in the trial.” However, this is also true for the Smith (1987) trial, which included 
only 62% of the initial participants in the analysis (above). Eby (1984 p. 20-21) described: 
“Of 146 original volunteers, 120 subjects returned reports. Initially, to use as much of the data as 
possible, we analyzed the 80 complete reports from 108 subjects who had been ill for 10 days or 
less at the start of treatment. ... this report is restricted to those 65 subjects who reported being ill 
for 3 days or less before starting the experiment.” Singh and Das use an inclusion criterion 
“interventions commenced within three days of participants developing common cold symptoms”. 
Given such a criterion, Eby’s post-randomization restriction to 65 subjects who were ill for 3 days 
or less before the treatment started is relevant data. In any case, Singh and Das should treat Eby 
(1984) and Smith (1987) trials consistently, so that both are included or excluded on the basis of 
the high rate of participants not included in the analysis. 
Singh and Das further criticise the Eby (1984) trial: “The trial relied on subjective 
assessment of symptoms by subjects.” However, this applies to essentially all zinc and common cold 
studies. In evidence-based medicine, the subjective symptoms are most essential outcomes. 
Subjective symptoms determine whether a patient goes to work or school, stays at home, or visits 
a physician. Double-blinding prevents systematic bias in the subjective assessment of symptoms, 
and therefore “subjective” per se cannot cause bias in a double-blind trial. Furthermore, if Singh 
and Das consider that “subjective assessment” is a basis to exclude the Eby (1984) trial, they should 
apply the same criterion to the other trials. 
Singh and Das also comment on the Eby (1984) trial: “Inclusion criteria were not 
adequately addressed and therefore there may have been potential for selection bias to occur.” 
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In randomized trials, the primary concern is the comparability of trial arms, so that there are no 
systematic differences that could lead to bias. All randomized trials use inclusion criteria of some 
kind, but that has nothing to do with the question whether the trial arms are comparable. Inclusion 
criteria are relevant when we consider the possibility to generalize the results, but not when 
considering the internal validity of a trial.
Finally, Singh and Das conclude their criticism of the Eby (1984) trial: “In addition, no 
information was provided on how allocation to treatment groups was concealed, the power of the 
study was not stated and viral studies were not conducted”. First, in most other zinc and common 
cold studies there is no information about how allocation was concealed (i.e. how blinding was 
maintained). Second, statistical power is relevant when planning a trial, but not after the trial is 
concluded, since the confidence interval gives the same information. Third, given that the primary 
goal in evidence-based medicine is to find out whether a treatment has clinically important effects, 
viral studies are not relevant. All these issues are missing in most of the zinc and common cold 
studies. Thus, if Singh and Das consider that these arguments give a sound basis to exclude the Eby 
trial, they should apply the same criteria also to the other trials. 
In the Characteristics of excluded studies table, Singh and Das comment on the Turner 
(2000) trial: “Poor methodological quality. Not a randomised trial”. However, Turner writes 
“Subjects who met the criteria for randomization to treatment were randomly assigned to 1 of 
the 4 treatments in accordance with the drug-randomization code” (p. 1202), [for induced colds:] 
“Subjects were randomized to receive study medication 24 h after challenge if they had a total daily  
symptom score ≥3” (p. 1203), [for natural colds:] “Subjects who presented to the study sites with 
a common-cold illness of ≤1 calendar day’s duration (effectively 36 h), reported ≥2 different 
symptoms, and had a total symptom score of ≥2 were randomized to receive 1 of the 3 treatments” 
(p. 1203). Thus, the statement by Singh and Das is false, unless they have information that 
disproves the text of the Turner (2000) report. In such a case, they should present their evidence. 
The Turner (2000) trial was reported as a randomized placebo-controlled double-blind study, and 
there is no basis to claim that it was of “poor methodological quality”.
5) Different methods of administering zinc should be analyzed separately
The majority of the zinc trials examined zinc lozenges in the western countries. Three trials by 
Kurugol (2006a, 2006b, 2007) and one trial by Vakili (2009) administered zinc as syrup or tablets; 
however, all these trials were carried out in low-income countries, Turkey and Iran. Thus, it is 
possible that the benefit of zinc supplementation in these trials is caused by biological mechanisms 
that are different from the mechanisms of the zinc lozenges, which are intended to be dissolved 
slowly in the mouth. The daily dose of zinc in the Kurugol and Vakili studies varied from 10 to 30 
mg per day, whereas the total daily dose of zinc in the zinc lozenge studies varied from 
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30 to 207 mg per day [2]. Thus, it is possible, or probable, that the benefits of the low dose zinc 
supplementation found by Kurugol and Vakili are explained by a sub-optimal dietary intake of zinc 
by children in Turkey and Iran. In contrast, it is possible that high dose zinc is needed in the 
lozenges to get benefit from them. 
Although Singh and Das restrict their systematic review to tablets, syrup and lozenges, 
they should also take a look at the other zinc literature. A few studies have examined the use of 
nasal administration of zinc to treat colds and found significant benefit [3,4]. Still, patients should 
not be exposed to intranasal zinc, since there are cases of anosmia caused by such a therapy [5]. 
Nevertheless, the benefit of local application of zinc to the nose indicates that the effect of zinc 
lozenges may be caused by local effects in the mouth-throat region, instead of systemic effects such 
as those caused by the ingestion of tablets and syrup. Therefore it is inappropriate to pool the tablet 
and syrup trials with the lozenge trials. This is a good example of the apples and oranges problem.
6) The duration of the common cold should not be dichotomized
Singh and Das present three tables which show “number of participants symptomatic after 
N days of treatment”, N being 3, 5 and 7. Dichotomization of continuous variables has been 
criticized [6]. Moreover, there is no need to dichotomize the duration of colds when analyzing the 
zinc lozenge trials. Although several trials did not report the mean and SD for the duration of colds 
in the trial arms, all of them reported data that makes it possible to calculate the mean and SD for 
cold duration [2]. The use of continuous outcome for common cold duration would also simplify 
the review as three redundant tables can be removed.
7) Duration of the common cold should be normalized so that placebo groups have length 100%
There is substantial variation in the duration of colds in the placebo groups of the zinc lozenge 
trials, from 5.1 days to 9.0 days and 10.8 days [2]. Although part of this variation is evidently 
caused by random variation, it is also caused by actual variations in the severity of disease in 
different patient groups and in differences in outcome definitions. Therefore, the relative effect 
of zinc on the common cold duration should be calculated in percentages, because the relative effect 
partly adjusts for the variations between patient groups and outcome definitions.
For example, if a 6-day cold is shortened by 1 day, it is not equivalent to a 1-day cold being 
shortened by the same amount although both differences are equal in absolute units. Consequently, 
it is much more reasonable to calculate the relative effect of zinc, so that a 6-day cold shortened 
by 2 days and a 1-day cold shortened by 0.33 days both correspond to an equivalent 33% reduction. 
Calculating the relative effect corresponds to the normalization of all control groups to an episode 
duration of one unit or 100%. Therefore, in our Cochrane review on vitamin C and the common 
cold we calculate the relative effect [7]. The use of relative effect in the analysis of common cold 
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duration corresponds to using the risk ratio in the analysis of binary data.
In their Analysis 1.1, Singh and Das pool the results by the SMD method, which means 
normalizing the duration by the SD (i.e. 1 unit in the scale corresponds to the SD of each study). 
However, using such a scale (SD units) is very difficult for an ordinary reader to understand. 
In their abstract, Singh and Das write: “Intake of zinc is associated with a significant reduction 
in the duration (standardised mean difference (SMD) -0.97)”. However, reporting should always 
give the unit of the measurement. In the SMD method, the unit is the SD unit. Thus, the above 
sentence should be re-written more accurately: “zinc shortened the duration of colds by 0.97 SD 
units”. Such accurate reporting would reveal the main problem of the SMD procedure: what does 
the SD-unit mean? 
I pooled the results of three large-dose zinc acetate lozenge trials and I found that “zinc 
shortened the duration of colds by 42%” [2], which is easy to understand. Most people can form 
an opinion whether 42% is small or large, but few people can form an opinion whether 0.97 SD 
units is small or large, or whether it is more or less than 42%. Thus, a relative scale would make 
the analysis of zinc trials easier to understand for the ordinary readers compared with the SD scale. 
The Cochrane Handbook comments (9.2.3.2): “The standardized mean difference [SMD] is used 
as a summary statistic in meta-analysis when the studies all assess the same outcome but measure 
it in a variety of ways (for example, all studies measure depression but they use different 
psychometric scales).” Thus, the SMD can be useful, for example, in psychiatry. In the case of 
common cold duration, the relative effect in percentages is much easier for readers.
8) Subgroup analysis should be carried out
Singh and Das write in the Background section that a “significant correlation between total
daily dosages of positively charged zinc species and a reduction in the mean duration of common 
colds” has been reported. Therefore, the daily dose of zinc should be considered in the statistical 
analysis. However, in their Result section Singh and Das claim that “subgroup analysis was not 
possible as there were not enough studies for each variable.” This is not correct. 
As noted above, there is a 6-fold variation in the total zinc dose (30 to 207 mg per day [2]) 
in the zinc lozenge studies. Given that the results of the zinc lozenge trials diverge so that some 
found no effect whereas some others found highly significant benefit, the relation between the dose 
and effect should be analyzed. Dose-response relation is a basic concept in pharmacology. 
I analyzed 13 zinc lozenge trials and divided them into three subgroups on the basis of the total 
daily dose of zinc and the type of lozenge [2]. None of five trials with the lowest doses of zinc 
found benefit of the lozenge, suggesting that they may have been using too low a dose. In the high-
dose trials, greater benefit was seen in three trials with zinc acetate, and smaller benefit in five 
non-acetate trials [2]. Further research should focus, in particular, on high doses of zinc acetate 
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(providing 80-90 mg/day of zinc) [2]. Thus, subgroup analysis is possible and it indicates a path 
to research that is needed. The syrup and tablet studies with children in the low-income countries 
should be presented as a separate group, on a separate Analysis table.
9) Pooling the adverse effects of all zinc trials is unsound
Eby has pointed out that the adverse effects of zinc lozenges, such as bad taste, can be explained 
largely by the differences in the composition of the lozenges [8-10]. In their Discussion, Singh and 
Das acknowledge this possibility: “the increased incidence of bad taste and nausea ... may have 
been related to the use of different ligands (gluconate, acetate) rather than to zinc itself.” In 
addition, it is obvious that dissolving a high zinc dose lozenge slowly in the mouth causes different 
adverse effects compared with ingesting a low zinc dose tablet or syrup straight to 
the stomach. Nevertheless, Singh and Das combine the adverse effects of the tablet and the zinc 
lozenge trials together as if they could estimate a “universal adverse effect of zinc” in the dose range 
of 15 to 192 mg per day. Nevertheless, the lack of “mouth irritation” by zinc syrup in 
the Kurugol studies (Analysis 2.19) is fully uninformative for a reader who is interested in 
the possible adverse effects of zinc lozenges. 
Thus, it would be much more informative to summarize the adverse effects as text, instead 
of pooling the results of such different trials. In the most recent zinc acetate lozenge trial, there were 
no significant differences between the zinc and placebo groups in the occurrence of adverse effects 
although the daily dose was 92 mg (Prasad 2008). Thus, it seems possible to formulate zinc 
lozenges that have minimal adverse effects. Furthermore, a patient suffering from acute adverse 
effects such as bad taste can simply stop taking the lozenges, whereas those who don’t suffer from 
such adverse effects could benefit from the lozenges. 
Although Singh and Das restrict their systematic review to treating the common cold, 
they should also take a look at other zinc literature for information about zinc safety. For certain 
patients, zinc has been administered at high doses, 150 mg/day, for therapeutic purposes for months 
[2,11-12]. On the basis of such long-term studies with high zinc doses, there does not seem to be 
any basis for assuming that treating the common cold for a week with high doses of zinc (80-90 
mg/day) in the form of lozenges might cause unanticipated harm.
10) Credit should be given to earlier work on the same topic
In their Introduction, Singh and Das write “The last review of all available RCTs of zinc for the 
common cold was published in 1999”, which is erroneous. Although it is not reasonable to discuss 
in detail all the earlier literature on the topic, the main reviews should be cited and briefly 
commented. Jackson’s [13] and Caruso’s [14] systematic reviews on zinc and the common cold 
were published after 1999. In the Discussion section, RevMan proposes a subtitle “Agreements and 
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disagreements with other studies or reviews”. Evidently, the same issue can be discussed under 
some other title. In any case, it would be important for Singh and Das to describe to what extent 
their review agrees and disagrees with the earlier reviews, such as [13,14]. If the conclusions do not 
differ from earlier reviews, then a new review does not increase our understanding about the topic. 
If the conclusions are different, then the reasons for the differences should be briefly discussed.
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